Navigation Links
Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
Date:7/12/2012

SUNNYVALE, Calif., July 12, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for human disorders including Parkinson's disease and Traumatic Brain Injuries (TBI) centered on its proprietary anti-apoptotic therapeutic protein known as MANF, today announced that its President & CEO Gerald E. Commissiong will be presenting a corporate overview today, July 12th, 2012, to be broadcast live from OneMedForum 2012 Conference at 11:20am ET from the Metropolitan Club in New York City. To watch the webcast live, click on the link http://www.onemedplace.com/forum/webcast/ .

EVENT  INFORMATION AT A GLANCE:

WHO: Gerald Commissiong, President and Chief Executive Officer

WHEN: July 12th, 2012 at 11:20am ET

WHERE: Metropolitan Club, New York City

WEBCAST: http://www.onemedplace.com/forum/webcast/

About OneMedForum 2012

OneMedPlace Trans-Atlantic Conference is the definitive conference in North America for fast-growing and emerging healthcare and life sciences companies. The 3rd annual New York Conference will bring together these emerging companies with venture and strategic investors within a unique networking and educational forum. Thought leaders in the disruptive technologies space across a variety of healthcare divisions will present both strategic insights and investment ideas to an international audience of the industry's movers and shakers.

This year, OneMedPlace explores the exciting investment opportunities, challenges and forward looking strategies in four sectors on the cusp of significant change:
- Diagnostics
- Health Information
- Oncology
- Regenerative Medicine.

The OneMedForum NY was recognized by Mayor Michael R. Bloomberg as an important event supporting innovation in the healthcare and life science industries "giving them the support, guidance and information they need to raise capital and develop innovative new ideas." Bloomberg proclaimed June 29th - 30th in the city of New York as "OneMedForum Day."

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and TBI. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS:
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408.737.2734 x 102
pr@amarantus.com


'/>"/>
SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
5. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
6. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... Portland, Oregon (PRWEB) , ... December 08, 2016 ... ... modules and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or ... do not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module ...
(Date:12/8/2016)... ... 08, 2016 , ... KBioBox llc announced today the launch ... developed a sophisticated “3 click” gene dditing off target analysis program and a ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016  Soligenix, ... late-stage biopharmaceutical company focused on developing and commercializing ... an unmet medical need, announced today the long-term ... with SGX942 (dusquetide), a first-in-class Innate Defense Regulator ... in head and neck cancer patients undergoing chemoradiation ...
Breaking Biology Technology:
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)... , Nov 15, 2016 Research and Markets ... Forecast to 2021" report to their offering. ... ... 16.18 Billion by 2021 from USD 6.21 Billion in 2016, growing ... Growth of the bioinformatics market is driven by the growing ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):